USD
GBP
CNY
EUR
INR
JPY
MYR
ZAR
KRW
THB
Advances and Growth Opportunities in RNA Vaccines
Advances and Growth Opportunities in RNA Vaccines
Technology Innovations and Investments Bolster Next-generation Prophylactic and Therapeutic RNA Vaccines
20-Dec-2022
Global
Technology Research
$4,950.00
Special Price $4,207.50 save 15 %
Description
RNA therapeutics and vaccines have been around for a long time, but the COVID-19 pandemic enabled their mass-market commercialization. Industry players saw mRNA vaccines developed for COVID-19 as effective for reducing the impact of the SARS-CoV-2 virus in populations. Moderna emerged as the first player to develop and commercialize an mRNA vaccine for COVID-19, followed by others such as Pfizer and BioNTech. mRNA is the first form of RNA vaccine to complete clinical trials and commercialization. Frost & Sullivan’s analysis shows industry participants are developing mRNA vaccines for influenza, HIV, and cancer.
RNA vaccine development is research intensive, with newer RNA modifications giving rise to more unique forms like self-amplifying mRNA (saRNA) and circular RNA vaccines. RNA design and optimization are essential to obtain RNA forms that suit vaccine development and provide the expected outcomes. saRNA vaccines are considered the next-generation RNA vaccines with improved properties and more advantages over mRNA vaccines. Meanwhile, circular RNA vaccines are emerging due to enhanced properties such as stability and higher protein expressions. It is a new RNA vaccine with high potential in the early stages of R&D and clinical trials.
Apart from research on RNA forms, RNA vaccine delivery systems and route of administration are also deciding factors in their success. To achieve maximum potential, researchers should deliver RNA vaccines through effective delivery systems that retain their potency.
Increased global demands for COVID-19 vaccines led to the manufacturing of mRNA vaccines in a short time to cater to large populations. Vaccine developers adopted digital technologies, expanded manufacturing units and capabilities, and increased collaborations with contract development and manufacturing companies to achieve such humongous targets. Expanding RNA vaccine manufacturing will increase the vaccine capacity and reduce large-scale manufacturing costs. This will ensure that the vaccine is affordable and allow vaccine developers to provide them to developing countries at a subsidy.
This report includes the following:
• Reasons for RNA vaccines emerging as a promising category of therapeutics
• Technological developments
• Digital biomanufacturing-driven changes in RNA vaccine development
• Newer modes of delivery
• Progress of clinical trials since the approval of the first RNA vaccine
• Global adoption rate
• Prospects for RNA vaccine developers
RESEARCH: INFOGRAPHIC
This infographic presents a brief overview of the research, and highlights the key topics discussed in it.Click image to view it in full size
Table of Contents
Why Is It Increasingly Difficult to Grow?The Strategic Imperative 8™: Factors Creating Pressure on Growth
The Strategic Imperative 8™
The Impact of the Top 3 Strategic Imperatives on the Ribonucleic Acid (RNA) Vaccine Industry
Growth Opportunities Fuel the Growth Pipeline Engine™
Research Methodology
Scope of Analysis
Segmentation
A Growing Shift Toward Developing RNA Vaccines
RNA Vaccines Overcome Limitations of Conventional Vaccines
Global Trends in RNA Vaccine Development
Growth Drivers
Growth Restraints
Types of RNA Vaccines and Technology Readiness Level (TRL)
Design and Modifications Improve Synthetic RNA Vaccine Production
Industry Players with RNA Vaccine Modification Platforms
Advanced Platforms Improve RNA Vaccine Designs and Processes to Produce High-quality Vaccines
Industry Players with AI-based RNA Design Platforms
The Lack of Well-developed Manufacturing Processes Slow RNA Vaccines Production Rates
Overcoming RNA Vaccine Manufacturing Bottlenecks to Meet Increased Demand
New Initiatives in RNA Vaccine Development and Manufacturing Platforms
Digitalization Will Transform RNA Vaccine Manufacturing
Developments in RNA Vaccine Delivery Systems
Developments in RNA Vaccine Delivery Systems (continued)
Industry Players Developing RNA Vaccine Delivery Platforms
New Formulations Increase the Shelf-life and Maximize the Delivery Potential of the RNA Vaccine
Newer Developments in RNA Vaccine Administration Routes
Needle-free Vaccine Delivery Administration Routes for mRNA Vaccines
RNA Vaccines Clinical Pipelines
Increased RNA Vaccine Programs Globally
Prophylactic RNA Vaccines
Therapeutic RNA Vaccines
mRNA Vaccines
Ongoing Developments by mRNA Vaccine Developers
saRNA Vaccines
Ongoing Developments by saRNA Vaccine Developers
Circular RNA Vaccines
Priority Disease Areas for RNA Vaccine Developers
Disease Focus Areas and Players Developing RNA Vaccines
RNA Vaccine Development and Manufacturing Industry Players
Future Opportunities for RNA Vaccines
A Dynamic Global Ecosystem Showcasing the Growth Potential of RNA Vaccines
A Dynamic Global Ecosystem Showcasing the Growth Potential of RNA Vaccines (continued)
Development of Innovative Vaccine Manufacturing Units and Capacity Expansion
Collaborations Among RNA Vaccine Developers
Collaborations Among RNA Vaccine Developers (continued)
Growth Opportunity 1: Global Infrastructure Development for RNA Vaccine Manufacturing and Delivery
Growth Opportunity 1: Global Infrastructure Development for RNA Vaccine Manufacturing and Delivery (continued)
Growth Opportunity 2: RNA Modifications and Design Improvements
Growth Opportunity 2: RNA Modifications and Design Improvements (continued)
Growth Opportunity 3: Improving Delivery Systems and Formulations
Growth Opportunity 3: Improving Delivery Systems and Formulations (continued)
Technology Readiness Levels (TRL): Explanation
Active RNA Vaccine Pipelines
Active RNA Vaccine Pipelines (continued)
Active RNA Vaccine Pipelines (continued)
Active RNA Vaccine Pipelines (continued)
Active RNA Vaccine Pipelines (continued)
Active RNA Vaccine Pipelines (continued)
Active RNA Vaccine Pipelines (continued)
Active RNA Vaccine Pipelines (continued)
Overcoming Delivery Challenges in RNA Vaccines
Your Next Steps
Why Frost, Why Now?
Legal Disclaimer
Growth dialog™
A tailored session with you where we identify the:- Strategic Imperatives
- Growth Opportunities
- Best Practices
- Companies to Action
Impacting your company's future growth potential.
Popular Topics
| Deliverable Type | Technology Research |
|---|---|
| Author | Neeraja Vettekudath |
| Industries | Healthcare |
| No Index | No |
| Is Prebook | No |
| Keyword 1 | RNA therapeutics and vaccines |
| Keyword 2 | mRNA Vaccines Market |
| Keyword 3 | mRNA vaccine for COVID-19 |
| Podcast | No |
| WIP Number | DA7D-01-00-00-00 |